With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Four years ago, Bristol management changed course and established the company as a pure play biopharma. Now, with the launch of Yervoy for metastatic melanoma and a late-stage pipeline that is chock-full, the strategy appears about to pay off. CEO Lamberto Andreotti and R&D president Elliott Sigal talked with IN VIVO about the launch of Yervoy and how Bristol, relying on R&D productivity, not diversification, is on track to overcome the extensive patent losses ahead.
You may also be interested in...
Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.